Clinical Trial Update: Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of multiple ascending doses of GC021109 in adults with mild to moderate Alzheimer's disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GC021109

Snippet

Sponsor: GliaCure, Inc. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED